Open Nav

Cytosen Therapeutics

  • Trent Carrier, CytoSen

Gain presence in the investment community

  • Date:Wednesday, October 17
  • Time:2:00 PM - 2:15 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:CytoSen Therapeutics is a private biopharmaceutical company bringing innovation to NK cell therapy by generating large numbers of highly-active natural killer cells with its particle-based “expansion and activation” process. Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer. Unlike many cellular immune products being investigated today, CytoSen’s unique, patented methods produce scalable cellular immunotherapeutics that have the potential to treat a myriad of cancer types through both personalized and universal donor sources. Our NK Cell Expansion and Activation Technology is the future in NK cell therapies, unparalleled among commercial solutions for generating large doses of primary NK cells with the highest anti-tumor activity.
  • Company Website:
  • Company HQ City:Winter Springs, Florida
  • Company HQ Country:United States
  • Company HQ State:Florida                        
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Cytosen PM21 Technology
  • Development Phase of Primary Product:Pre-Clinical
  • Total Amount Raised to Date, In All Rounds:$10 million
Trent Carrier